[HTML][HTML] Determining Thrombogenicity: Using a Modified Thrombin Generation Assay to Detect the Level of Thrombotic Event Risk in Lupus Anticoagulant-Positive …

P Bradáčová, L Slavík, J Úlehlová, E Kriegová, E Jará… - Biomedicines, 2023 - mdpi.com
The aim of this study was to determine the thrombogenicity of lupus anticoagulant (LA)
antibodies using a modified thrombin generation assay (TGA) with the addition of activated …

Prevalence of antiphospholipid antibody syndrome misclassification in an academic health system

M Ballif, SR Vazquez, J Saunders, DM Witt - Thrombosis Research, 2023 - Elsevier
Abstract Purpose Antiphospholipid Antibody Syndrome (APS) is a complex autoimmune
disorder that includes a combination of laboratory criteria and clinical events (thrombosis …

Stroke risk in multiple sclerosis: A critical appraisal of the literature

T Doskas, E Dardiotis, GD Vavougios… - International Journal …, 2023 - Taylor & Francis
Observational studies suggest that the occurrence of stroke on multiple sclerosis (MS)
patients is higher compared to the general population. MS is a heterogeneous disease that …

Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodies' types and titers—cross-sectional study of Serbian …

A Djokovic, L Stojanovich, N Stanisavljevic… - Clinical …, 2022 - Springer
Objectives Antiphospholipid syndrome (APS) is multisystem autoimmune coagulopathy with
antiphospholipid antibodies (aPL) in its ground, manifested as a primary disease (PAPS) or …

Applying index of circulating anticoagulant to mixing tests with lupus anticoagulant screen and confirm reagents can distinguish with high specificity between lupus …

O Kumano, J Amiral, C Dunois… - International Journal …, 2021 - Wiley Online Library
Background Lupus anticoagulants (LA) are detected by prolongation of clotting times for
dilute Russell's viper venom time (dRVVT) and activated partial thromboplastin time (APTT) …

Check for updates

RA Marlar - Hemostasis and Thrombosis: Methods and Protocols, 2023 - books.google.com
Venous thromboembolism (VTE) occurs typically in the veins of the lower extremities and/or
as pulmonary embolism. There is a myriad of causes of VTE ranging from provoked causes …

[PDF][PDF] Levels and avidities of antiphosphatidylethanolamine antibodies in patients with thrombotic events and immunologically-mediated diseases.

O Kuchar, M Petrackova, M Kalousova… - … Papers of the …, 2023 - biomed.papers.upol.cz
Aims. Antiphosphatidylethanolamine antibodies (aPE) represent one type of
antiphospholipid antibody (aPL) directed against the neutral phospholipids …

[HTML][HTML] Антитела к комплексу фосфатидилсерин/протромбин у пациентов с антифосфолипидным синдромом

ТМ Решетняк, ФА Чельдиева… - Терапевтический …, 2022 - cyberleninka.ru
Цель. Определить значение антител к комплексу фосфатидилсерин/протромбин (анти-
ФС/ПТ) у пациентов с системной красной волчанкой (СКВ) и антифосфолипидным …

Antibodies to the phosphatidylserine/prothrombin complex in the diagnosis of antiphospholipid syndrome

TM Reshetnyak, FA Cheldieva, MV Cherkasova… - Terapevticheskii …, 2022 - ter-arkhiv.ru
Aim. To determine the significance of antibodies to the phosphatidylserine/prothrombin
complex (aPS/PT) in patients with systemic lupus erythematosus (SLE) antiphospholipid …

Determinantes clínicos y biológicos en la estratificación del riesgo de recurrencias trombóticas arteriales y venosas en una cohorte de pacientes con síndrome …

J Lozano Herrero - Proyecto de investigación:, 2022 - digitum.um.es
Objetivos: El síndrome antifosfolípido (SAF) es una trombofilia que se caracteriza por una
alta tasa de recurrencias trombóticas. Se han identificado factores de riesgo y se han …